European Commission approves Agamree (vamorolone) to treat Duchenne muscular dystrophy – Santhera Pharma
Santhera Pharmaceuticals announces that Agamree (vamorolone) has been approved in the European Union (EU) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age… read more.
